Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Method Validation

Method Validation

View Detailed Analysis

Analytics Overview

33
Form 483s Issued
7
483s converted to WL
37
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
20 Sep 2024
Aarti Drugs Limited
Drugs
21 Jun 2024
Cipla Limited
Drugs
14 Jun 2024
Biocon Biosphere Limited
Drugs
12 Jun 2024
Hikma Pharmaceuticals USA Inc.
Drugs
07 Jun 2024
Dr. Reddy's Laboratories Limited
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Pratik S Upadhyay
4
1
Justin A Boyd
4
2
Christina K Theodorou
3
0
Arsen Karapetyan
3
1
Joanne E King
3
1
TITLE/ COMPANY Issue Date Status Details
Test procedures is not scientifically sound and appropriate to ensure that raw materials, intermediates, and APIs, conform to established standards
Aarti Drugs Limited
20 Sep 2024 Normal Justification: The observation mentions an inhouse test method which is not validated, directly linking to method validation lapses.
Excerpt: A review of the corresponding Analytical Method Validation Report confirmed that the method is not validated for impurities.
View Details
The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.
Cipla Limited
21 Jun 2024 Normal Justification: Validation ensures the accuracy and reproducibility of test methods, which is critical for product quality.
Excerpt: The following commercial drug products test methods, including in-house and compendial test methods, were not validated, verified or transferred appropriately.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Biocon Biosphere Limited
14 Jun 2024 Normal Justification: The major issues are resultant from inadequate validation procedures, affecting reliability and compliance of test methods.
Excerpt: The microbial enumeration test method validation titled "Study Report to Perform the Method Suitability... does not include the strain Aspergillus brasiliensis... The test method for (b) (4) identification testing does not include gas chromatography analysis for the limit of (b) (4).
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures
Hikma Pharmaceuticals USA Inc.
12 Jun 2024 Normal Justification: Method validation is directly affected as the observation highlights missing validation characteristics, which are crucial for ensuring test reliability.
Excerpt: omits established characteristics for conducting a method validation, such as but not limited to, Accuracy and instrument comparability.
View Details
Analytical methods were not validated or verified under the actual conditions of use.
Dr. Reddy's Laboratories Limited
07 Jun 2024 Normal Justification: The observation directly mentions the failure to validate and verify test methods under actual conditions, which is a core aspect of method validation.
Excerpt: The following test methods, including in-house and compendial test methods, were not validated or verified appropriately for the commercial APIs.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.